IL6ST
ENSG00000134352
Target class
Membrane receptor
Chromosome
5
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- IL6ST
- Gene name
- Interleukin 6 cytokine family signal transducer
- Gene symbol
- IL6ST
- Protein name
- Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
- GP130
- CD130
- sGP130
- IL-6RB
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Fibronectin type III domain containing|Interleukin receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 214.04
- Tissue specificity (Gini)
- 0.342
- Tissue specificity (tau)
- 0.736
- KEGG gene identifiers
- hsa:3572
- Protein interaction confidence
- 0.870018
- Protein interaction partners
- 56
- R-HSA-1059683
- R-HSA-6788467
- R-HSA-8984722
- R-HSA-9020956
- R-HSA-9958825
- End position
- 55995022
- Start position
- 55935095
- Chromosome
- 5
- Strand
- Reverse
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted .
- Golgi apparatus
- Plasma membrane
- PubMed 19915009
- PubMed 24629561
- Tissue specificity (tau)
- 0.73623
- Expression inequality (Gini)
- 0.342156
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 214.04
- Adipose - Visceral (Omentum)
- 117.22
- Lung
- 116.88
- Nerve - Tibial
- 116.5
- Adipose - Subcutaneous
- 113.36
Expression in transcripts per million
- Cells - Cultured fibroblasts214.04
- Adipose - Visceral (Omentum)117.22
- Lung116.88
- Nerve - Tibial116.5
- Adipose - Subcutaneous113.36
- Cervix - Ectocervix108.85
- Artery - Coronary108.36
- Artery - Aorta101.02
- Breast - Mammary Tissue100.24
- Cervix - Endocervix99.6
- Artery - Tibial97.44
- Thyroid96.7
- Fallopian Tube92.44
- Esophagus - Muscularis85.07
- Uterus84.42
- Esophagus - Gastroesophageal Junction78.02
- Ovary77.36
- Bladder76.97
- Vagina69.96
- Spleen65.83
- Colon - Sigmoid65.53
- Adrenal Gland64.88
- Prostate64.8
- Brain - Spinal cord (cervical c-1)64.74
- Minor Salivary Gland54.45
And 29 more, listed on the interactive page.
- GO:0002675
- GO:0002821
- GO:0007259
- GO:0008283
- GO:0008284
- GO:0010575
- GO:0010613
- GO:0019221
- GO:0034097
- GO:0038154
- GO:0038165
- GO:0042102
- GO:0043066
- GO:0043524
- GO:0045669
- GO:0045747
- GO:0048861
- GO:0060576
- GO:0070102
- GO:0070106
- GO:0070120
- GO:0097696
- GO:1901731
- GO:0005576
- GO:0005886
- GO:0005896
- GO:0005900
- GO:0016020
- GO:0045121
- GO:0070062
- GO:0070110
- GO:0140370
- GO:7770013
- GO:0004896
- GO:0004897
- GO:0004915
- GO:0004923
- GO:0004924
- GO:0005125
- GO:0005127
- GO:0005138
- GO:0005515
- GO:0015026
- GO:0019838
- GO:0019981
- GO:0042802
- GO:0045509
- GO:0097110
Related records
Trials (560)
- "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
- A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
- A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
- A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
- A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
- A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
- A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
- A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
- A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
- A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
Drugs (5)
- Ciliary neurotrophic factor
- Oprelvekin
- Satralizumab IL6Ralpha/GP130 antagonist
- Tocilizumab
- Vobarilizumab